Jim Cramer Says He Was Wrong for Selling Johnson & Johnson for the Charitable Trust

Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s game plan for this week. Cramer explained why he sold the stock for the Charitable Trust, as he commented:

“Wednesday morning brings two stocks that are hard to keep down. Johnson & Johnson and Charles Schwab. J&J has become a pure play on pharma by spinning off its orthopedics division. That’s smart because orthopedics happens to be a commoditized business. Meanwhile, its pharma business has some of the best drugs in the pipe, and they really shine without the knee, hip, and joint business holding them back. J&J still has a talc overhang of people willing to sue the company for all sorts of cancers allegedly caused by asbestos in their old baby powder. Now, I’m not saying these lawsuits don’t matter; that would be heartless. I am saying that they no longer matter to the stock, now that J&J’s fighting each individual claim, which can be daunting to the plaintiff’s bar. I was intimidated by the lawsuits myself, and sold it for the investing club. That was wrong. I regret listening to the Circe sirens.”

Pixabay/Public Domain

Johnson & Johnson (NYSE:JNJ) develops and sells healthcare products, including pharmaceuticals and medical technologies, with treatments in immunology, oncology, neuroscience, cardiovascular care, and infectious diseases.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.